Cwm LLC Increases Position in Waters Corporation $WAT

Cwm LLC grew its position in shares of Waters Corporation (NYSE:WAT) by 71.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,422 shares of the medical instruments supplier’s stock after purchasing an additional 1,837 shares during the period. Cwm LLC’s holdings in Waters were worth $1,326,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. IFP Advisors Inc lifted its stake in Waters by 65.4% during the 2nd quarter. IFP Advisors Inc now owns 134 shares of the medical instruments supplier’s stock worth $51,000 after acquiring an additional 53 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in Waters during the second quarter worth about $53,000. MUFG Securities EMEA plc acquired a new stake in shares of Waters during the second quarter worth about $61,000. Creative Financial Designs Inc. ADV lifted its position in shares of Waters by 533.3% during the second quarter. Creative Financial Designs Inc. ADV now owns 190 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 160 shares in the last quarter. Finally, Steph & Co. purchased a new position in shares of Waters in the second quarter valued at approximately $73,000. 94.01% of the stock is owned by institutional investors and hedge funds.

Waters Price Performance

Waters stock opened at $381.97 on Monday. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a fifty day simple moving average of $381.61 and a 200-day simple moving average of $337.09. The stock has a market cap of $22.75 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 3.19 and a beta of 1.16. Waters Corporation has a 12-month low of $275.05 and a 12-month high of $423.56.

Waters (NYSE:WAT) last posted its quarterly earnings results on Thursday, May 19th. The medical instruments supplier reported $2.29 earnings per share for the quarter. The company had revenue of $608.55 million for the quarter. Waters had a return on equity of 36.59% and a net margin of 20.89%. Equities analysts expect that Waters Corporation will post 12.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WAT has been the topic of several recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Waters in a research note on Wednesday, October 8th. JPMorgan Chase & Co. upped their price objective on Waters from $300.00 to $325.00 and gave the stock a “neutral” rating in a research report on Thursday, October 9th. Wells Fargo & Company increased their price objective on Waters from $385.00 to $415.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. TD Cowen boosted their target price on Waters from $345.00 to $390.00 and gave the stock a “hold” rating in a research note on Wednesday, November 5th. Finally, Redburn Partners set a $390.00 price target on Waters in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $392.19.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.